Center for Infectious Disease and Vaccine Research; Division of Infectious Diseases and Immunology, Department of Medicine
We characterized human monoclonal antibodies (MAbs) cloned from influenza virus-infected patients and from influenza vaccine recipients by complement-dependent lysis (CDL) assay. Most MAbs active in CDL were neutralizing, but not all neutralizing MAbs can mediate CDL. Two of the three stalk-specific neutralizing MAbs tested were able to mediate CDL and were more cross-reactive to temporally distant H1N1 strains than the conventional hemagglutination-inhibiting and neutralizing MAbs. One of the stalk-specific MAbs was subtype cross-reactive to H1 and H2 hemagglutinins, suggesting a role for stalk-specific antibodies in protection against influenza illness, especially by a novel viral subtype which can cause pandemics.
Rights and Permissions
Publisher PDF posted as allowed by the publisher's author rights policy at http://journals.asm.org/site/misc/ASM_Author_Statement.xhtml.
J Virol. 2011 Dec;85(24):13463-7. doi: 10.1128/JVI.05193-11. Epub 2011 Oct 12. Link to article on publisher's site
Terajima, Masanori; Cruz, John; Co, Mary Dawn T.; Lee, Jane-Hwei; Kaur, Kaval; Wrammert, Jens; Wilson, Patrick C.; and Ennis, Francis A., "Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies" (2011). Infectious Diseases and Immunology Publications and Presentations. 238.